Backed by top investors
Our Science
With the right tuning and targeting, bispecific antibodies can effectively treat solid tumors.
In the past decade, immune-engaging bispecific antibodies have risen to the forefront of blood cancer treatments. However, the bispecific design parameters used for maximizing therapeutic windows in blood cancers do not translate well to solid tumors.
To achieve efficacy without dose limiting toxicities, our immune-engaging bispecific antibodies are designed to eliminate solid tumors by tuning potencies of immune-engaging arms and driving tumor localization. Our best-in-class therapeutics will provide clinicians flexibility with dosing strategies and combination regimens to deliver optimal results for patients.
NGS-based antibody discovery enables rapid development of diverse binding arm collections. Our fixed-light chain format allows for flexible pairing of immune effector and tumor targeting arms. Our proprietary functional and developability screens assess the desired set of potencies and identify clinically viable molecules.
of bispecific antibodies with optimal therapeutic windows for treating solid tumors.
for rapid antibody development and efficient operating model.
for delivery of multiple clinical programs.
for synergistic advancement of clinical assets.
Shelley Force Aldred, PhD
Chief Executive Officer | Co-Founder
Nathan Trinklein, PhD
Chief Scientific Officer | Co-Founder
Prior experience together
News
Events
Listen to Luke Timmerman's interview with Shelley Force Aldred and Nathan Trinklein, Rondo Therapeutics' inspiring co-founders. Learn the story of seasoned entrepreneurs, building a company for the fourth time to deliver best-in-class, immune engager therapeutics for solid tumors.
